This company seems to have been delisted
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
KemPharm
KMPH
$5.81
Share price
-0.34%
Change (1 day)
6.61%
Change (1 year)
Categories
KemPharm (KMPH) - Total liabilities
Total liabilities on the balance sheet as of December 2022 : $29.72 Million USD
According to KemPharm's latest financial reports the company's total liabilities are $29.72 Million USD. A company’s total liabilities is the sum of all current and non-current debts and obligations.
KemPharm - Total liabilities on balance sheet (from 2014 to 2022)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $29.72 M | 410.42% |
| 2021-12-31 | $5.82 M | -92.5% |
| 2020-12-31 | $77.62 M | -8.64% |
| 2019-12-31 | $84.96 M | -8.95% |
| 2018-12-31 | $93.31 M | -15.15% |
| 2017-12-31 | $0.10 B | 6.17% |
| 2016-12-31 | $0.10 B | 57.32% |
| 2015-12-31 | $65.84 M | 73.2% |
| 2014-12-31 | $38.01 M | 42.4% |
| 2013-12-31 | $26.69 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 | $7.91 B | 26,541.88% | 🇮🇪 Ireland |
 | $36.87 M | 24.07% | 🇺🇸 USA |
 | $0.17 B | 473.48% | Cayman Islands |
 | $0.85 B | 2,777.22% | 🇺🇸 USA |